Table 4.

Median percent change from baseline in biomarker concentration in patients who achieved or did not achieve LDA (DAS28-CRP <3.2) at week 24

	Placebo		Sarilumab 200 mg q2w
	LDA achieved (n = 37)	LDA not achieved (n = 91)	LDA achieved (n = 72)	LDA not achieved (n = 59)
CRP
Week 2	1.2	−2.9	−95.0**	−83.5
Week 24	−31.9**	−4.2	−96.9**	−90.2
C1M
Week 2	4.5	2.2	−55.8*	−45.1
Week 24	−16.8*	−4.3	−65.7**	−54.1
C2M
Week 2	0	3.4	0*	−14.3
Week 24	0	3.5	0	−6.7
MMP-3
Week 2	−2.0	2.3	−7.2	−3.3
Week 24	−9.7	0.4	−47.2	−34.2
OPG
Week 2	−5.1	1.6	−6.5*	−0.9
Week 24	−1.9	−1.8	−4.6	0.9
sRANKL
Week 2	−4.7	−0.8	−7.9	−2.3
Week 24	−16.2*	−0.8	−39.7	−25.8

Percent change from baseline in biomarkers transformed in rank was compared between responder and nonresponder patients at week 24 using an analysis of variance (ANOVA)-type method, with response, visit, and response-by-visit interaction as fixed effects, rank-transformed baseline biomarker value and rank-transformed baseline biomarker-value-by-visit interaction as fixed covariates, and assuming an unstructured covariance structure. The model was run separately by treatment group (sarilumab 200 mg q2w and placebo).

C1M collagen type I MMP-cleaved fragment, C2M collagen type II MMP-cleaved fragment, CRP C-reactive protein, DAS28-CRP 28-joint disease activity score by CRP, LDA low disease activity, MMP matrix metalloproteinase, MTX methotrexate, OPG osteoprotegerin, q2w every 2 weeks, sRANKL soluble receptor activator of nuclear factor-kB ligand. *Nominal p < 0.05 vs nonresponder. **Nominal p < 0.01 vs nonresponder